Table S2. Demographic and clinical variables and their association with response, progression-free survival and overall survival

Variables / Response / PFS / OS
Responder / Nonresponder / P value / Median (months) / 95%CI / P value / Median (months) / 95%CI / P value
No. / % / No. / %
Age / 0.527 / 0.615 / 0.295
≤median / 20 / 47.6 / 22 / 52.4 / 6.2 / 4.1-8.3 / 17.1 / 11.6-22.6
>median / 15 / 40.5 / 22 / 59.5 / 7.5 / 6.3-8.7 / 19.8 / 17.6-22.0
Sex / 0.206 / 0.770 / 0.144
Male / 19 / 38.8 / 30 / 61.2 / 6.7 / 4.8-8.6 / 20.3 / 17.5-23.1
female / 16 / 53.3 / 14 / 46.7 / 7.5 / 5.4-9.6 / 17.1 / 15.0-19.2
ECOG PS / 0.435 / 0.131 / 0.001
0 / 19 / 48.7 / 20 / 51.3 / 7.9 / 5.8-10.0 / 23.5 / 16.2-30.8
≥1 / 16 / 40.0 / 24 / 60.0 / 6.0 / 4.6-7.4 / 15.4 / 11.4-19.4
Primary tumor site / 0.501 / 0.884 / 0.192
Colon / 23 / 41.8 / 32 / 58.2 / 7.5 / 5.2-9.8 / 18.1 / 14.8-21.4
Rectum / 12 / 50.0 / 12 / 50.0 / 5.9 / 4.5-7.3 / 21.6 / 14.8-28.4
Differentiation grade / 0.796 / 0.067 / 0.734
Well/moderate / 27 / 43.5 / 35 / 56.5 / 7.9 / 6.1-9.7 / 19.4 / 17.0-21.8
Poor / 8 / 47.1 / 9 / 52.9 / 5.8 / 3.1-8.5 / 15.7 / 0-35.7
Previous surgery / 0.553 / 0.483 / 0.956
Yes / 25 / 42.4 / 34 / 57.6 / 7.1 / 5.4-8.8 / 19.6 / 16.9-22.3
No / 10 / 50.0 / 10 / 50.0 / 7.5 / 3.9-11.1 / 19.4 / 11.0-27.9
Previous adjuvant chemotherapy / 0.898 / 0.582 / 0.865
Yes / 10 / 45.5 / 12 / 54.5 / 7.1 / 3.4-10.8 / 19.6 / 14.9-24.3
No / 25 / 43.9 / 32 / 56.1 / 6.9 / 5.0-8.8 / 19.4 / 15.7-23.1
Metastatic site / 0.193 / 0.099 / 0.040
Single / 17 / 53.1 / 15 / 46.9 / 8.4 / 6.6-10.2 / 22.1 / 19.3-24.9
Multiple / 18 / 38.3 / 29 / 61.7 / 6.1 / 5.1-7.1 / 17.1 / 14.5-19.7
Liver metastasis / 0.704 / 0.631 / 0.333
Yes / 20 / 42.6 / 27 / 57.4 / 7.1 / 4.8-9.4 / 20.6 / 19.1-22.1
No / 15 / 46.9 / 17 / 53.1 / 6.9 / 5.2-8.6 / 17.1 / 14.2-20.0
Lung metastasis / 0.876 / 0.839 / 0.441
Yes / 9 / 42.9 / 12 / 57.1 / 7.1 / 5.2-9.0 / 19.2 / 15.0-23.4
No / 26 / 44.8 / 32 / 55.2 / 7.1 / 5.6-8.6 / 19.4 / 15.8-23.0

ECOG PS eastern cooperative oncology group performance status.